

ATS 2009 • San Diego

The American Thoracic Society's 105th International Conference, May 15 to 20, 2009



We help the world breathe
PULMONARY • CRITICAL CARE • SLEEP

News Release

FOR RELEASE MAY 17, 2009 at 8:15 a.m. PDT

FOR MORE INFORMATION, CONTACT:

Keely Savoie or Brian Kell

ksavoie@thoracic.org or bkell@thoracic.org

ATS Office: 212-315-8620 or 212-315-6442 (until May 13)

Cell phones: 917-860-5814 (KS) or 516-305-9251 (BK)

ATS Press Room: 619-525-6323, 619-525-6324 or 619-525-6325 (May 15 to 20)

Poster session time: May 17: 8:15 a.m. to 10:45 a.m.

Poster viewing time: May 17: 8:15 a.m. to 9:15 a.m.

Poster discussion time: May 17: 9:15 a.m. to 10:45 a.m.

Location: San Diego Convention Center, Room 6F (Upper Level)

This research will also be presented at the “Late Breaking Clinical Trials” Scientific Symposium Tuesday, May 19th 1:30-4:00 p.m., San Diego Convention Center, Room 7 A-B (Upper Level).

Large Clinical Trial Finds Pirfenidone May Help Lung Function in IPF Patients

ATS 2009, SAN DIEGO—A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.

In a Phase III clinical study program called “CAPACITY,” investigators discovered that the oral anti-fibrotic and anti-inflammatory agent, pirfenidone, could slow the deterioration of lung capacity in patients suffering from IPF.

The researchers presented their findings on Sunday, May 17, at the American Thoracic Society’s 105th International Conference in San Diego.

The CAPACITY trial consisted of two multi-national, randomized, double-blind, placebo-controlled Phase III trials (CAPACITY 1 and CAPACITY 2) designed to evaluate the safety and efficacy of pirfenidone in IPF patients with mild to moderate impairment in lung function. The primary endpoint of change in percent predicted forced vital capacity (FVC) at week 72 was met with statistical significance in CAPACITY 2 ($p=0.001$), along with the secondary endpoints of categorical change in FVC and progression-free survival (PFS), defined as time to either death, a 10-percent decrease in FVC or a 15-percent decrease in DL_{CO} (diffusing capacity of the lung for carbon monoxide). The primary endpoint was not met in CAPACITY 1 ($p=0.501$), but evidence of a pirfenidone treatment effect on the primary endpoint was observed at several periods in that trial. Importantly, greater than 80 percent of patients in the trials completed treatment and greater than 90 percent completed the study.

An exploratory analysis of pooled data from both trials revealed that treatment with pirfenidone resulted in a 30-percent relative reduction in the percentage of patients who experienced an absolute decline in percent predicted FVC of at least 10 percent. This magnitude of decline is considered clinically meaningful, as a 10-percent decline in percent predicted FVC has been shown in multiple studies to be an independent predictor of mortality in patients with IPF. Exploratory analyses of pooled data from the two CAPACITY studies also demonstrated a statistically significant treatment effect on the primary endpoint of change in percent-predicted FVC at week 72, progression-free survival time and change in six-minute walk test distance.

“While it was disappointing that the primary endpoint was not met in CAPACITY 1, important consistencies between the two CAPACITY studies were observed in the overall treatment effect of pirfenidone,” said Paul Noble, M.D., co-chair of the CAPACITY program and professor of medicine and chief of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center. “The treatment effect observed in the CAPACITY studies was generally consistent with that observed in the Phase III study in IPF patients conducted by Shionogi in Japan. Collectively, these three studies give us a very good sense of the impact that pirfenidone has on the progression of IPF over at least one year.”

According to the National Heart, Lung, and Blood Institute, about 200,000 Americans have idiopathic pulmonary fibrosis, a condition that scars tissue deep in the lungs. Most patients are diagnosed with the disease in their 50s and 60s, and many people live only three to five years after being diagnosed. There are no approved medications in the United States or Europe to treat the disease. Pirfenidone is approved in Japan for the treatment of IPF.

A total of 779 patients were enrolled in the CAPACITY trials at 110 sites in 11 countries. The mean age of participants was 66. To be eligible for the study, patients had to have a definitive diagnosis made by high-resolution CT scan or by biopsy, and a FVC \geq 50 percent of predicted values and a DL_{CO} \geq 35 percent of predicted value.

Dr. Roland du Bois, M.D., professor of medicine at National Jewish Health, in Denver, Colo., and CAPACITY co-chair, concurred that these studies were very encouraging for IPF sufferers and added that “the safety and tolerability of pirfenidone was reassuring. The principal side effects experienced by patients in the studies were gastrointestinal discomfort and photo-sensitivity, both of which were manageable in the majority of patients.”

The CAPACITY trials follow a Phase III clinical study conducted in Japan that was reported at the American Thoracic Society’s 2008 International Conference in Toronto. That trial, which demonstrated the ability of pirfenidone to reduce the decline of lung capacity and improve progression-free survival, served as the basis for the Japanese regulatory authorities’ approval of the medicine for the treatment of IPF in Japan.

Dr. du Bois concluded, “When taken in the context of the urgent unmet medical need for new medicines to treat IPF patients, the collective efficacy and safety data from the two CAPACITY studies, corroborated by a similar study in Japan, make a case for the use of pirfenidone in this disease setting.”

InterMune, Inc., the developer of the medication, is preparing a New Drug Application (NDA) for pirfenidone for the treatment of IPF, which it expects to submit to the FDA in the summer of 2009, to be followed by a Marketing Authorization Application (MAA), which will be submitted to the European Medicines Agency (EMA) around the end of 2009. Meanwhile, all patients in the study have been offered pirfenidone as part of an open-label, long-term safety study called RECAP.

###

Session # C98: “Late-Breaking Clinical Trials”

Session # A23: “Interstitial Lung Disease: Outcomes and Selected Clinical Issues”

Abstract # 5158: “The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF)”

Poster Board # 216

**The CAPACITY trials were funded by InterMune, Inc.*

[Close Window](#)

ATS 2009 · San Diego International Conference

Abstract Number: 5158

Contact/Presenting Author: Paul Noble

Department/Institution: Duke University Medical Center

Address: 106 Research Drive, DUMC Box 103000

City/State/Zip/Country: Durham, NC, 27710

Phone: (919) 681-0355 **Fax:** **E-mail:** paul.noble@duke.edu

ATS member: Yes **Student or in training:** No

Funding Source: InterMune, Inc.

Abstract Category: 09.21 - Interstitial Lung Disease

Presentation format: Either Poster or Oral

[Preview Disclosure](#)

Travel Award: No

Publication of email address: No

I confirm that all authors listed on this abstract have knowledge of the abstract submission:
Yes

Title: The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF)

P. Noble¹, C. Albera², W. Bradford³, U. Costabel⁴, D. Kardatzke³, T. King, Jr⁵, S. Sahn⁶, J. Szwarcberg³, D. Valeyre⁷ and R. du Bois⁸. ¹Duke University, Durham, NC; ²University of Turin, Italy; ³InterMune, Inc., Brisbane, CA; ⁴Ruhrlandklinik, Essen, Germany; ⁵UCSF, San Francisco, CA; ⁶MUSC, Charleston, SC; ⁷Assistance Publique-Hôpitaux, Paris, France and ⁸National Jewish, Denver, CO.

Introduction: PFD is an oral antifibrotic agent shown in trials in Japan to be safe and efficacious in IPF patients. CAP I and II are global registration trials conducted concurrently to further assess the safety and efficacy of PFD in IPF patients.

Methods: Patients were randomized to receive PFD or placebo (PBO) TID until 72 weeks after the last patient enrolled. In CAP I, patients received PFD 2403 mg/d or PBO; in CAP II, patients received PFD 2403 mg/d, PFD 1197 mg/d, or PBO. Eligibility criteria included a confident clinical and radiologic diagnosis, FVC \geq 50%, and DLco \geq 35%. The primary endpoint was change in % FVC at Wk 72.

Results: A total of 779 patients (CAP I: 344, CAP II: 435) were enrolled at 110 sites in 11 countries. Treatment is complete, but only blinded, preliminary data are available. Most patients

were Caucasian, male, and the mean age was 66. HRCT scans met criteria for definite IPF in > 90% of patients; all others had a diagnostic biopsy. Over 97% of surviving, transplant-free patients completed the Wk 72 Visit.

Conclusions: CAP I and II are robust, global Phase III trials to assess the safety and efficacy of PFD in IPF patients. Preliminary blinded results demonstrate successful enrollment of the target population and extremely high rates of patient retention. Final study results will be presented.

Demographic and Baseline Characteristics

	CAP I (N=344)	CAP II (N=435)
Mean Age (years)	66.9	66.4
Male (%)	71.8	71.5
Caucasian (%)	98.8	96.3
Mean A-a gradient (mm Hg)	17.1	17.7
Mean % FVC	74.0	75.6
Mean % DL _{CO}	47.6	46.4
Definite IPF on HRCT (%)	89.2	93.6